- Home
- MDCX vs CTXR Comparison
MDCX vs CTXR Comparison
Compare MDCX & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDCX | CTXR |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | 16 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6M | 18.9M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | MDCX | CTXR |
|---|---|---|
| Price | $0.30 | $0.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $14.50 | $6.00 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $0.48 |
| 52 Week High | $7.73 | $2.38 |
Technical Indicators
Market Signals| Indicator | MDCX | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 51.02 |
| Support Level | $0.29 | $0.63 |
| Resistance Level | $0.36 | $0.99 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 48.17 | 80.08 |
Price Performance
Historical ComparisonAbout MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.